1 / 19

Marketing Group Presentation

Marketing Group Presentation. Cost Analysis by Anawat Pinisakul Intellectual Property Laws in Thailand by Phanit Ratasuk Health Insurance in Thailand by Chate Jaikunya FDA Thai by Manaswee Arayasiri Southeast Asia Market by Myat Htay Kyi HIV in China by Wang Xiaofeng.

Download Presentation

Marketing Group Presentation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Marketing Group Presentation • Cost Analysis by Anawat Pinisakul • Intellectual Property Laws in Thailand by Phanit Ratasuk • Health Insurance in Thailand by Chate Jaikunya • FDA Thai by Manaswee Arayasiri • Southeast Asia Market by Myat Htay Kyi • HIV in China by Wang Xiaofeng

  2. Cost and Financing Aspects of Providing Anti-Retroviral Therapy Marketing Group of AIDS Drug By Mr. Anawat Pinisakul EVD998498 Advisor Dr. Maria Kartalou Dr. Suvit Loprasert

  3. Today Presentation • Introduction • Background • Treatment of AIDS by drug • Contents • Cost and financing aspect • Cost-saving and cost-effectiveness • Conclusions

  4. Introduction • The HIV/AIDS was first recognized in the early 1980s. • Treatment options were limited. • AZT drug (Zidovudine) was approved by USA’s FDA in 1987. • This drug is now widely used in North America, Europe and Australia • Other anti-retrovirals (ARVs)

  5. Introduction • In contrast, ARVs are not yet widely available in developing countries. • Asia • Africa • Latin America • ARVs combination therapies • Prolong life • Prevent HIV-infected progression • Reduce transmission of HIV from mother to children

  6. Contents • Cost of providing anti-retroviral therapy • Total cost implication of providing anti-retroviral therapy • Total cost implications of providing anti-retroviral therapy in comparison with available resources • Cost-saving potential and cost-effectiveness of anti-retroviral therapy • Financing anti-retroviral therapy

  7. Cost of providing anti-retroviral therapy • Three types of drug • Nucleoside reverse transciptase inhibitors • Protease inhibitors • Non- Nucleoside reverse transciptase inhibitors

  8. }

  9. Cost of providing anti-retroviral therapy

  10. Total cost implication of providing anti-retroviral therapy Estimated Number of People North America Oceania Sub-Saharan Africa Eastern Europe Northeast Asia Western Europe Latin America Caribbean SE Mediterranean Southeast Asia Geographic Region

  11. Total cost implication of providing anti-retroviral therapy Estimated Cost ($billion) Northeast Asia Sub-Saharan Africa Eastern Europe North America Oceania Western Europe Latin America Caribbean SE Mediterranean Southeast Asia

  12. Total cost implications of providing anti-retroviral therapy in comparison with available resources

  13. Total cost implications of providing anti-retroviral therapy in comparison with available resources • Number of patients • Cost of treatment • GDP • Health expenditures

  14. Cost-saving potential and cost-effectiveness of anti-retroviral therapy • Cost-saving potential • AZT therapy • Reduced health care costs in comparison with not receive drug • Triple-combination therapies • Cost save in 4.6 times per capita income • Cost-effectiveness • AZT therapy • Prolong life • Triple-combination therapies • Reduce medical costs

  15. Financing anti-retroviral therapy • High cost with ARV therapy • Financing care may not be sufficient • Health care financing • Taxation • Social insurance system • Private insurance • User fees • Community financing schemes

  16. Financing anti-retroviral therapy • Private insurance companies • Difficult for patient to receive helping • Employers in the USA try to exclude AIDS patients from group insurance polices • Public sector • In Maryland, Medicaid • 65% of AIDS patients

  17. Conclusions • ARV therapy does appear affordable and cost-effective in high-income countries • Consideration • Number of HIV patients • Income of population • Type of drug • Government section

  18. Thank You! • Dr. Maria Kartalou • Dr. Suvit Loprasert • MIT Staff • CRI Staff • Our Classes

  19. THE END

More Related